Nyxoah SA (NYXH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Company Overview - Nyxoah is a medtech company focused on neurostimulation solutions for obstructive sleep apnea, listed on Nasdaq and Euronext under the ticker NYXH [2] - The company has recently obtained FDA approval for its product, marking a significant milestone in its history [2] Market Opportunity - The addressable market for obstructive sleep apnea in the U.S. is estimated to include 450,000 to 500,000 eligible patients, representing a market opportunity of approximately $10 billion [3] - The market is largely underpenetrated, with only 8% of the total eligible patient population currently receiving therapy [4]